3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
29
Urinary Bladder Neoplasms
26
Carcinoma, Renal Cell
22
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
7
Neoplasm Metastasis
7
Squamous Cell Carcinoma of Head and Neck
6
Ureteral Neoplasms
5
Prostatic Neoplasms
5
Ovarian Neoplasms
5
Melanoma
5
Carcinoma, Merkel Cell
5
Urethral Neoplasms
4
Triple Negative Breast Neoplasms
4
Stomach Neoplasms
4
Small Cell Lung Carcinoma
3
Kidney Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Penile Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Lung Neoplasms
2
Kidney Diseases
2
Head and Neck Neoplasms
2
Urothelial Cancer
1
Urologic Neoplasms
1
Turcot syndrome
1
Testicular Neoplasms
1
Interventions
avelumab
1
Cystectomy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non-metastatic Muscle Invasive Bladder Cancer
×
avelumab
×
Genitourinary
×
Clear all
NCT03674424
2025-02-26
AURA
Jules Bordet Institute
Phase 2
Completed
137 enrolled